Business
Esperion Reports First Quarter 2025 Financial Results
– Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – – Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y to $34.9 Million – – Bempedoic Acid Earned Level 1a Recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes – – Expanded Development Portfolio with Introduction of Novel Program Targeting Primary Sclerosing Cholangitis (PSC) – – Confere
About this update from Esperion Therapeutics, Inc.
[{"type":"image","alt":"Esperion Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Esperion Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":94,"url":"https://media.zenfs.com/en/globenewswire.com/4890074d6b0f0d0a38002f9d11a84e21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/l5dS5p4arlgcAzQpBUpJMQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/4890074d6b0f0d0a38002f9d11a84e21","width":300,"height":94}},"lazy":false},{"type":"text","content":"– Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y –","length":147,"tagName":"p"},{"type":"text","content":"– Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y to $34.9 Million –","length":66,"tagName":"p"},{"type":"text","content":"– Bempedoic Acid Earned Level 1a Recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes –","length":158,"tagName":"p"},{"type":"text","content":"– Expanded Development Portfolio with Introduction of Novel Program Targeting Primary Sclerosing Cholangitis (PSC) –","length":116,"tagName":"p"},{"type":"text","content":"– Conference Call and Webcast Today at 8:00 a.m. ET –","length":53,"tagName":"p"},{"type":"text","content":"ANN ARBOR, Mich., May 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today reported financial results for the first quarter ended March 31, 2025, and provided a business update.","length":183,"tagName":"p"},{"type":"text","content":"“Throughout the first quarter, we continued to make important progress advancing our three pillars for growth: revenue growth, portfolio expansion and pipeline advancement,” stated Sheldon Koenig, President and CEO of Esperion. “We were excited to surpass our one millionth prescription for our bempedoic acid products in the U.S. and, while the overall lipid market was flat in the first quarter of 2025, we are implementing initiatives to drive growth by introducing new marketing around statin intolerance and leveraging recent inclusion in clinical guidelines. Importantly, we have increased our field reimbursement specialists three-fold to ensure that physicians can write prescriptions with confidence in its coverage.”","length":726,"tagName":"p"},{"type":"text...